Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Increases By 391.3%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 7,860,000 shares, a growth of 391.3% from the October 31st total of 1,600,000 shares. Currently, 30.0% of the shares of the company are sold short. Based on an average daily volume of 63,190,000 shares, the days-to-cover ratio is currently 0.1 days.

Insider Buying and Selling

In other CERo Therapeutics news, major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of CERo Therapeutics stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $0.10, for a total transaction of $325,000.00. Following the completion of the transaction, the insider now owns 22,620,783 shares in the company, valued at approximately $2,262,078.30. The trade was a 12.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Stuart M. Sloan sold 532,486 shares of the stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $0.10, for a total value of $53,248.60. Following the completion of the sale, the insider now directly owns 21,067,956 shares in the company, valued at approximately $2,106,795.60. This represents a 2.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.00% of the stock is currently owned by insiders.

CERo Therapeutics Stock Up 37.6 %

CERo Therapeutics stock traded up $0.06 during midday trading on Wednesday, reaching $0.20. 63,552,133 shares of the company traded hands, compared to its average volume of 20,757,527. CERo Therapeutics has a 12 month low of $0.06 and a 12 month high of $12.80. The business has a 50 day moving average of $0.12 and a two-hundred day moving average of $0.29.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.